Crago, Aimee M.
Memorial Sloan Kettering Cancer Center · Weill Cornell Medicine
6 papers on CoChatORCID 0000-0002-2965-752X
Most cited papers
- Verified
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2021) · Nature Communications
Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis
Cited by 441
- Verified
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology
Sarcoma Diagnosis and TreatmentAdvanced Breast Cancer Therapies
Cited by 399
- Verified
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications
Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer
Cited by 232
- Verified
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget
Cancer-related Molecular PathwaysTelomeres, Telomerase, and Senescence
Cited by 142
- Verified
ATRX is a regulator of therapy induced senescence in human cells
Kovatcheva, M., Liao, W., Klein, M. E., Robine, N., Geiger, H., Crago, A. M., Dickson, M. A., Tap, W. D., Singer, S., & Koff, A. (2017) · Nature Communications
Telomeres, Telomerase, and SenescenceGenomics and Chromatin Dynamics
Cited by 89
- Verified
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets
Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., et al. (2013) · Science Signaling
Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer
Cited by 86
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free